InMode (NASDAQ:INMD) Issues FY25 Earnings Guidance

InMode (NASDAQ:INMD) updated its FY25 earnings guidance on Tuesday. The company provided earnings per share guidance of $1.95-$1.99 for the period, compared to the consensus earnings per share estimate of $1.98. The company issued revenue guidance of $395-$405 million, compared to the consensus revenue estimate of $413.47 million.

Analysts Set New Price Targets

Several research analysts have recently issued reports on INMD shares. Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Tuesday. BTIG Research began coverage on InMode in a research note on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target for the company. Finally, Barclays lifted their price objective on InMode from $26.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $23.00.

InMode Stock Performance

Shares of NASDAQ INMD traded up $0.41 during midday trading on Wednesday, reaching $17.91. The stock had a trading volume of 493,584 shares, compared to its average volume of 864,740. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 9.69 and a beta of 2.13. The stock has a 50-day moving average of $17.44 and a 200-day moving average of $17.19. InMode has a 12-month low of $14.87 and a 12-month high of $26.80.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.